Loading organizations...
Q Bio provides a comprehensive health assessment platform, building a "digital twin" from integrated advanced imaging, genetic, and physiological data. Leveraging physics, AI, biology, and medicine, it offers personalized insights for proactive health management and early detection. Services include full body MRI, genetic measurements, wearable data, biometrics, and EKG, all analyzed by AI for physicians.
Jeffrey Kaditz and Michael Snyder, PhD, founded Q Bio. Kaditz, a Carnegie Mellon alumnus, established the company to transcend reactive healthcare. His insight centered on comprehensive data integration across biological systems, providing a quantifiable, predictive understanding of health for proactive intervention.
Q Bio serves individuals seeking detailed preventive insights, and clinics integrating advanced assessments. Operating its own clinic and collaborating with longevity institutions, its vision is to transform healthcare by mapping critical indicators and revealing future health dependencies for superior preventive decisions.
Q Bio has raised $111.0M across 4 funding rounds.
Q Bio has raised $111.0M in total across 4 funding rounds.
Q Bio has raised $111.0M across 4 funding rounds. Most recently, it raised $27.0M Other Equity in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 19, 2024 | $27M Venture Round | — | — | Announced |
| Jul 1, 2024 | $27M Series U | — | 305 Ventures, Amadeus Capital Partners, FirstMark Capital, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, Section 32, Valia Ventures, Vzvc, What IF Ventures, Andy Coravos, Kevin Hart, Yumin Choi, Andreessen Horowitz, Founders Fund, Kaiser Permanente, TELUS Ventures | Announced |
| Feb 1, 2020 | $40M Series B | Andreessen Horowitz | Amadeus Capital Partners, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, Vzvc, Kevin Hart | Announced |
| Dec 1, 2017 | $17M Series A | — | Amadeus Capital Partners, Khosla Ventures, Point72 Ventures | Announced |
Q Bio is a technology company that develops a clinical digital twin platform combining AI, physics, and biology to automate and transform the physical exam process. Its platform creates a comprehensive virtual model of a patient’s physiological and genetic data, enabling personalized health monitoring, risk assessment, and preventive care. Q Bio primarily serves healthcare providers and patients by offering detailed insights into health status and future risks, particularly for chronic diseases like cancer, diabetes, and cardiovascular conditions. The company has demonstrated growth momentum through successful deployment of its platform in its Redwood City clinic and partnerships with major longevity and healthcare organizations[1][2][4].
Founded in 2015, Q Bio was established by Jeffrey Kaditz, a serial entrepreneur and founder of Affirm; Dr. Michael Snyder, Chair of Genetics and Director of Personalized Medicine at Stanford University; and Dr. Garry Choy, a physician, radiologist, and former Chief Medical Information Officer at Massachusetts General Hospital. The idea emerged from the founders’ vision to create a “Star Trek MedBay” — a futuristic, comprehensive physical exam powered by AI and whole-body scanning technology. Early traction included backing from top venture capital firms such as Andreessen Horowitz, Khosla Ventures, Founders Fund, and SciFi VC, as well as a major investment from Kaiser Foundation Hospitals, validating the platform’s potential in personalized medicine[1][3][4].
Q Bio rides the growing trend of personalized medicine and digital health, leveraging advances in AI, genomics, and imaging to shift healthcare from reactive treatment to proactive prevention. The timing is critical as healthcare systems increasingly adopt digital tools to manage chronic diseases and improve patient outcomes cost-effectively. Market forces such as rising healthcare costs, demand for precision medicine, and technological maturation of AI and imaging create a favorable environment. By pioneering clinical digital twins, Q Bio influences the broader ecosystem by setting new standards for comprehensive health data integration and predictive analytics, potentially transforming how physical exams and preventive care are delivered[1][4].
Looking ahead, Q Bio is positioned to expand its clinical footprint and partnerships, scaling its platform to more healthcare providers and patient populations. Trends shaping its journey include advances in AI interpretability, integration with genomic and biomarker data, and growing consumer demand for personalized health insights. As digital twin technology matures, Q Bio’s influence may extend beyond preventive care into treatment simulation and precision therapeutics. Its success will depend on continued innovation, regulatory acceptance, and integration into mainstream healthcare workflows, potentially making the “physical exam of the future” a standard of care[1][4].
Q Bio has raised $111.0M in total across 4 funding rounds.
Q Bio's investors include 305 Ventures, Amadeus Capital Partners, FirstMark Capital, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, Section 32, Valia Ventures, VZVC, What If Ventures, Andy Coravos.
